What is RPRX's five-year median EV/EBITDA?

25.8x. Half of RPRX's weekly readings since May 2026 were higher and half were lower. This page has 285 weekly readings, from May 10, 2021 to Oct 19, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares RPRX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Royalty Pharma PLC (RPRX) valuation history

Health Care

$63.86

Latest weekly close · Market cap $35.6B

As of Oct 24, 2026

RPRX's EV/EBITDA of 28.8x has weekly readings only since May 2026, not enough history to rank yet.

Weekly EV/EBITDA since May 2026

EV/EBITDA each weekMiddle half of its readingsMedian 25.8×

Median: 25.8×
Low to high: 23.0×–28.8×
Versus median: +12%
History starts: May 2026

EV/EBITDA

n/anot ranked

EV/EBITDA needs more weekly history to be ranked.

Growth, last 12 months vs the year before

Revenue: +10%accelerating
EPS: -18%

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading

EV/EBITDA at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

RPRX EV/EBITDA at each year-end
Year-end	EV/EBITDA	5-year percentile
Dec 29, 2025	n/a	Too little history
Dec 30, 2024	n/a	Too little history
Dec 25, 2023	n/a	Too little history
Dec 26, 2022	n/a	Too little history
Dec 27, 2021	n/a	Too little history

Health Care peers on EV/EBITDA

Each percentile compares a stock with its own last five years.

Compare RPRX with peers

Health Care peers of RPRX on EV/EBITDA
Stock	EV/EBITDA	Versus its own history	5-year percentile
AXSMAxsome Therapeutics Inc	n/a	Not ranked	n/a, not ranked
BMYBristol Myers Squibb	9.6×	Within its usual range	45
CORTCorcept Therapeutics Inc	n/a	Not ranked	n/a, not ranked
ELANElanco Animal Health Inc	n/a	Not ranked	n/a, not ranked
JAZZJazz Pharmaceuticals PLC	10.9×	Below its usual range	29

Appears in

Sector: Health Care
Screens: Stocks with Low P/E Ratios and Steady Revenue Growth
Stocks Below Their 5-Year Median P/E
Stocks Near Their Lowest P/E Ratios in 5 Years

Screen Health Care stocks the same way

Research on RPRX

No articles about RPRX yet. How valuation percentiles work

Loading peers and related research…

About this history

What is RPRX's current EV/EBITDA?: RPRX's EV/EBITDA of 28.8x has weekly readings only since May 2026, not enough history to rank yet.
What is RPRX's five-year median EV/EBITDA?: 25.8x. Half of RPRX's weekly readings since May 2026 were higher and half were lower. This page has 285 weekly readings, from May 10, 2021 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares RPRX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.